

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/913,516	08/15/2001		Katsumi Iga	074129-0488	9786
22428	7590	07/11/2006		EXAMINER	
	ND LAR	DNER LLP	GEORGE, KONATA M		
SUITE 500 3000 K STREET NW				ART UNIT	PAPER NUMBER
WASHINGTON, DC 20007				1616	
				DATE MAILED: 07/11/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
	Office Action Summary	09/913,516	IGA ET AL.					
omeen canna,		Examiner	Art Unit					
	The MAILING DATE of this communication app	Konata M. George	1616					
Period fo	· · · · · · · · · · · · · · · · · · ·							
WHIC - External after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin vill apply and will expire SIX (6) MONTHS from 1. cause the application to become ABANDONE	N. nely filed the mailing date of this communication. (D) (35 U.S.C. § 133).					
Status								
1)⊠	Responsive to communication(s) filed on 30 M	arch 2006.						
	This action is FINAL . 2b)⊠ This action is non-final.							
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Disposit	ion of Claims							
4)🖂	4) Claim(s) 8,11-13,15,16,18-34,38 and 39 is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
, —	Claim(s) is/are allowed.							
-	☑ Claim(s) <u>8,11-13,15,16,18-34,38 and 39</u> is/are rejected.							
•	7) Claim(s) is/are objected to. B) Claim(s) are subject to restriction and/or election requirement.							
الــا(ه	claim(s) are subject to restriction and/o	r election requirement.						
Applicat	ion Papers							
	The specification is objected to by the Examine							
10) The drawing(s) filed on is/are: a) accepted or b) dijected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11)	Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex							
Priority (under 35 U.S.C. § 119							
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:								
	1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage								
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
" `	See the attached detailed Office action for a list	of the certified copies not receive	eu.					
Attachmer								
	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail D						
3) Infor	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) or No(s)/Mail Date	_ _	Patent Application (PTO-152)					

Application/Control Number: 09/913,516

Art Unit: 1616

DETAILED ACTION

Claims 8, 11-13, 15, 16, 18-34, 38 and 39 are pending in this application.

Action Summary

- 1. Applicant's request for reconsideration of the finality of the rejection of the last Office action is persuasive and, therefore, the finality of that action is withdrawn.
- 2. The rejection of claims 8, 11-13, 15, 16, 18, 19, 22-26, 29, 30, 32-34 and 38 under 35 U.S.C. 103(a) over SmithKline Beecham Co. in view of Katz et al. is hereby withdrawn with respect to applicants' arguments.

Response to Arguments

3. Applicant's arguments with respect to claims 8, 11-13, 15, 16, 18, 19, 22-26, 29, 30, 32-34 and 38 have been considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claim 34 is rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: steps requiring application to the skin or topical application.

Application/Control Number: 09/913,516

Art Unit: 1616

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claims 8, 11-13, 15, 16, 18-33, 38 and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over SmithKline Beecham Co. (WO 95/06410) in view of Sekine et al. (WO 97/28794 as translated by US 6,054,484) and RxList Monographs (1999).

SmithKline Beecham Co. ('410) discloses the use of angiotension II receptor antagonist as a medicament for the treatment of chronic inflammatory diseases, which can be formulated for transdermal delivery as a patch or membrane, and when formulating the composition topically the composition can contain non-toxic auxiliary substances such as emulsifying agent, polyols, etc. (page 28, lines 2-7 and page 29, lines 14-32). Claim 13, page 41, lines 29-33 teach that the angiotension II receptor antagonist is 1-(cyclohexyloxycarbonyloxy) ethyl-2-ethoxy-1- [(2'-(1H-tetrazol-5-yl) biphenyl-4-yl) methyl]-benzimidazole-7-carboxylate or pharmaceutically acceptable salt. The prior art does not teach the preparation comprising a fatty acid ester or the angiotension II antagonistic activity.

Sekine et al. discloses in Table 14, a cataplasm (see col. 5, lines 25-31 for description) comprising a fatty acid ester (isopropyl myristate at a concentration of 1%), a polyol (propylene glycol at a concentration of 10%) and a nonionic surfactant (coconut fatty acid diethanolamide at a concentration of 2%) (col. 20, lines 1-22). Column 7, lines

Application/Control Number: 09/913,516 Page 4

Art Unit: 1616

13-18 describe a formulation of a self-adhesive cataplasm by adding a polymer (polybutene) and gelatin.

RxList Monograph discloses information about 1-(cyclohexyloxycarbonyloxy) ethyl-2-ethoxy-1- [(2'-(1H-tetrazol-5-yl) biphenyl-4-yl) methyl]-benzimidazole-7-carboxylate also known as Candesaratan cilexetil.

Sekine et al. teaches the preparations using diclofenac sodium as the active agent. Column 1, lines 53-60 teach that diclofenac sodium has 1.5% solubility in water. RxList Monographs teach that Candesaratan cilexetil is practically insoluble in water. Therefore, when formulating a compound that is poorly soluble in water such as Candesaratan cilexetil into a transdermal delivery system, one of ordinary skill in the art could look to Sekine et al. as a method of formulating a compound that has poor solubility in water into a transdermal delivery device with the addition of compounds that can aid in penetration i.e. polyols, surfactants and fatty acids.

With respect to the angiotension II antagonistic activity, absent a clear showing of criticality, the determination of angiotension II antagonistic activity is within the skill of the ordinary worker as part of the process of normal optimization to achieve the desired results of the claimed composition.

Conclusion

6. Claims 8, 11-13, 15, 16, 18-34, 38 and 39 are rejected.

Application/Control Number: 09/913,516 Page 5

Art Unit: 1616

Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Konata M. George, whose telephone number is 571-

272-0613. The examiner can normally be reached from 8AM to 6:30PM Monday to

Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Johann Richter, can be reached at 571-272-0646. The fax phone numbers

for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have question on access to the Private Pair system, contact the Electronic

Business Center (EBC) as 866-217-9197 (toll-free).

Konata M. George

Patent Examiner

Technology Center 1600

Supervisory Patent Examiner

Technology Center 1600